Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 266

1.

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer.

Satoh T, Lee KH, Rha SY, Sasaki Y, Park SH, Komatsu Y, Yasui H, Kim TY, Yamaguchi K, Fuse N, Yamada Y, Ura T, Kim SY, Munakata M, Saitoh S, Nishio K, Morita S, Yamamoto E, Zhang Q, Kim JM, Kim YH, Sakata Y.

Gastric Cancer. 2014 Sep 5. [Epub ahead of print]

PMID:
25185971
[PubMed - as supplied by publisher]
2.

hTERT mediates norepinephrine-induced Slug expression and ovarian cancer aggressiveness.

Choi MJ, Cho KH, Lee S, Bae YJ, Jeong KJ, Rha SY, Choi EJ, Park JH, Kim JM, Lee JS, Mills GB, Lee HY.

Oncogene. 2014 Aug 25;0. doi: 10.1038/onc.2014.270. [Epub ahead of print]

PMID:
25151968
[PubMed - as supplied by publisher]
3.

Comparison of Melanoma Subtypes among Korean Patients by Morphologic Features and Ultraviolet Exposure.

Jang HS, Kim JH, Park KH, Lee JS, Bae JM, Oh BH, Rha SY, Roh MR, Chung KY.

Ann Dermatol. 2014 Aug;26(4):485-90. doi: 10.5021/ad.2014.26.4.485. Epub 2014 Jul 31.

PMID:
25143678
[PubMed]
Free PMC Article
4.

Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children.

Lim SM, Yoo CJ, Han JW, Cho YJ, Kim SH, Ahn JB, Rha SY, Shin SJ, Chung HC, Yang WI, Shin KH, Rho JK, Kim HS.

Cancer Res Treat. 2014 Aug 21. doi: 10.4143/crt.2013.157. [Epub ahead of print]

PMID:
25143049
[PubMed - as supplied by publisher]
Free Article
5.

Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.

Park JS, Jeung HC, Rha SY, Ahn JB, Kang B, Chon HJ, Hong MH, Lim S, Yang WI, Nam CM, Chung HC.

Cancer Chemother Pharmacol. 2014 Aug 9. [Epub ahead of print]

PMID:
25107569
[PubMed - as supplied by publisher]
6.

Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer.

Park HS, Jung M, Kim HS, Kim HI, An JY, Cheong JH, Hyung WJ, Noh SH, Kim YI, Chung HC, Rha SY.

Ann Surg Oncol. 2014 Aug 1. [Epub ahead of print]

PMID:
25081339
[PubMed - as supplied by publisher]
7.

High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients.

Lee HY, Ahn JB, Rha SY, Chung HC, Park KH, Kim TS, Kim NK, Shin SJ.

World J Surg Oncol. 2014 Jul 24;12:232. doi: 10.1186/1477-7819-12-232.

PMID:
25060774
[PubMed - in process]
Free PMC Article
8.

Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma.

Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page R, Bavbek S, Beck JT, Patel P, Cheung FY, Yadav S, Schiff EM, Wang X, Niolat J, Sellami D, Anak O, Knox JJ.

J Clin Oncol. 2014 Sep 1;32(25):2765-72. doi: 10.1200/JCO.2013.54.6911. Epub 2014 Jul 21.

PMID:
25049330
[PubMed - in process]
9.

Kaposi's Varicelliform-Like Eruption in a Patient Treated with Everolimus for Metastatic Renal Cell Carcinoma: Report of a Rare Case.

Hong S, Kim EH, Cho SB, Rha SY.

Case Rep Oncol. 2014 May 27;7(2):337-42. doi: 10.1159/000362925. eCollection 2014 May.

PMID:
24987353
[PubMed]
Free PMC Article
10.

A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer.

Kang YK, Rha SY, Tassone P, Barriuso J, Yu R, Szado T, Garg A, Bang YJ.

Br J Cancer. 2014 Aug 12;111(4):660-6. doi: 10.1038/bjc.2014.356. Epub 2014 Jun 24.

PMID:
24960402
[PubMed - in process]
11.

Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium.

Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood LA, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Kim JJ, Choueiri TK.

Eur Urol. 2014 Oct;66(4):704-10. doi: 10.1016/j.eururo.2014.05.034. Epub 2014 Jun 13.

PMID:
24931622
[PubMed - in process]
12.

Vascular soft-tissue sarcomas: a prognostic model from a retrospective single-center study.

Park KS, Kim HS, Cho YJ, Rha SY, Ahn JB, Yang WI, Lee YH, Suh JS, Shin KH, Roh JK.

Oncology. 2014;86(5-6):329-35. doi: 10.1159/000358804. Epub 2014 Jun 7.

PMID:
24925021
[PubMed - indexed for MEDLINE]
13.

Clinical features and treatment of collecting duct carcinoma of the kidney from the korean cancer study group genitourinary and gynecology cancer committee.

Kwon KA, Oh SY, Kim HY, Kim HS, Lee HY, Kim TM, Lim HY, Lee NR, Lee HJ, Hong SH, Rha SY.

Cancer Res Treat. 2014 Apr;46(2):141-7. doi: 10.4143/crt.2014.46.2.141. Epub 2014 Apr 22.

PMID:
24851105
[PubMed]
Free PMC Article
14.

Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer.

Zhang X, Zheng Z, Shin YK, Kim KY, Rha SY, Noh SH, Chung HC, Jeung HC.

Pathology. 2014 Jun;46(4):316-24. doi: 10.1097/PAT.0000000000000094.

PMID:
24798152
[PubMed - in process]
15.

First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the international metastatic renal cell carcinoma database consortium.

Harshman LC, Kroeger N, Rha SY, Donskov F, Wood L, Tantravahi SK, Vaishampayan U, Rini BI, Knox J, North S, Ernst S, Yuasa T, Srinivas S, Pal S, Heng DY, Choueiri TK.

Clin Genitourin Cancer. 2014 Oct;12(5):335-40. doi: 10.1016/j.clgc.2014.03.003. Epub 2014 Mar 15.

PMID:
24787966
[PubMed - in process]
16.

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.

Ko JJ, Choueiri TK, Rini BI, Lee JL, Kroeger N, Srinivas S, Harshman LC, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Vaishampayan UN, Agarwal N, Pal SK, Tan MH, Rha SY, Yuasa T, Donskov F, Bamias A, Heng DY.

Br J Cancer. 2014 Apr 15;110(8):1917-22. doi: 10.1038/bjc.2014.25. Epub 2014 Apr 1.

PMID:
24691425
[PubMed - indexed for MEDLINE]
17.

Ifosfamide-induced Fanconi syndrome with diabetes insipidus.

Leem AY, Kim HS, Yoo BW, Kang BD, Kim MH, Rha SY, Kim HS.

Korean J Intern Med. 2014 Mar;29(2):246-9. doi: 10.3904/kjim.2014.29.2.246. Epub 2014 Feb 27.

PMID:
24648810
[PubMed - in process]
Free PMC Article
18.

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.

Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, Kollmannsberger C, Rha SY, Bjarnason GA, Melichar B, De Giorgi U, Gr├╝nwald V, Davis ID, Lee JL, Esteban E, Urbanowitz G, Cai C, Squires M, Marker M, Shi MM, Escudier B.

Lancet Oncol. 2014 Mar;15(3):286-96. doi: 10.1016/S1470-2045(14)70030-0. Epub 2014 Feb 17.

PMID:
24556040
[PubMed - indexed for MEDLINE]
19.

Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients.

Wang Y, Choueiri TK, Lee JL, Tan MH, Rha SY, North SA, Kollmannsberger CK, McDermott DF, Heng DY.

Br J Cancer. 2014 Mar 18;110(6):1433-7. doi: 10.1038/bjc.2014.28. Epub 2014 Feb 18.

PMID:
24548864
[PubMed - indexed for MEDLINE]
20.

A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.

Alimohamed N, Lee JL, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Tantravahi S, Kollmannsberger C, North S, Rini BI, Choueiri TK, Heng DY.

Clin Genitourin Cancer. 2014 Aug;12(4):e127-31. doi: 10.1016/j.clgc.2013.12.003. Epub 2013 Dec 27.

PMID:
24485801
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk